NASDAQ:ADRO Aduro Biotech (ADRO) Stock Price, News & Analysis → Bigger Than NVIDIA? (From Behind the Markets) (Ad) Free ADRO Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$2.28▼$14.6052-Week Range N/AVolume171,500 shsAverage Volume162,237 shsMarket Capitalization$236.61 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Aduro Biotech alerts: Email Address Ad Behind the MarketsThis Weight Loss Company Can't Make Enough ProductA tiny pharmaceutical company is getting overwhelmed by a massive demand for its new weight loss marvel. They recently reported over 25,000 Americans are starting their drug each week - a 4X increase since December!Get the name of the company and their stock ticker here >>> About Aduro Biotech Stock (NASDAQ:ADRO)Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.Read More Ad Behind the MarketsThis Weight Loss Company Can't Make Enough ProductA tiny pharmaceutical company is getting overwhelmed by a massive demand for its new weight loss marvel. They recently reported over 25,000 Americans are starting their drug each week - a 4X increase since December!Get the name of the company and their stock ticker here >>> ADRO Stock News HeadlinesMay 4, 2024 | thetimes.co.ukBiotech’s Zandy Forbes: My lost family fortune and being the first to earn a livingFebruary 24, 2024 | morningstar.comAduro Clean Technologies Inc Ordinary SharesJanuary 3, 2024 | morningstar.comPT Adaro Energy Indonesia TbkDecember 2, 2023 | morningstar.comPT Adaro Energy Indonesia Tbk ADRONovember 16, 2023 | benzinga.comLegend Biotech Stock (NASDAQ:LEGN), Analyst Ratings, Price Targets, PredictionsNovember 10, 2023 | seekingalpha.comBret JensenNovember 6, 2023 | reuters.comConcord Biotech LtdJune 26, 2023 | thestreet.comAduro Biotech Pancreatic Cancer Immunotherapy Fails Mid-Stage StudyMarch 18, 2023 | finance.yahoo.comFrench biotech Sensorion does not expect any impact to its liquidity from SVB's closureMarch 15, 2023 | reuters.comSVB shock could have chilling effect on British biotech sectorMarch 15, 2023 | cnbc.comSVB fallout: The impacts on the biotech sectorDecember 17, 2022 | thestreet.comCancer Immunotherapy Remains Hot as Aduro Biotech Doubles in Value On IPO DebutNovember 30, 2022 | finance.yahoo.comAduro Selected for Shell GameChanger ProgramOctober 29, 2022 | barrons.comMerck’s CFO Says Biotech Deals are Getting DoneSeptember 28, 2022 | finance.yahoo.comPT Adaro Energy Indonesia Tbk (ADRO.JK)July 31, 2021 | barrons.comAdaro EnergySee More Headlines Receive ADRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aduro Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/04/2020Today6/17/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ADRO CUSIPN/A CIK1435049 Webwww.aduro.com Phone(206) 485-7051FaxN/AEmployees152Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($5.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,370,000.00 Net Margins-230.92% Pretax MarginN/A Return on Equity-101.73% Return on Assets-22.35% Debt Debt-to-Equity RatioN/A Current Ratio8.91 Quick Ratio8.91 Sales & Book Value Annual Sales$17.26 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$4.07 per share Price / BookN/AMiscellaneous Outstanding Shares16,212,000Free FloatN/AMarket Cap$236.61 million OptionableOptionable Beta0.40 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesEric L. DobmeierChairman, President & Chief Executive OfficerAlan GlicklichChief Medical OfficerKirk D. SchumacherSenior Vice President & General CounselTom FrohlichChief Business OfficerNoopur LiffickVP-Investor Relations & Corporate CommunicationsKey CompetitorsImmunomeNASDAQ:IMNMCentessa PharmaceuticalsNASDAQ:CNTAGyre TherapeuticsNASDAQ:GYREOPKO HealthNASDAQ:OPKCassava SciencesNASDAQ:SAVAView All Competitors ADRO Stock Analysis - Frequently Asked Questions How were Aduro Biotech's earnings last quarter? Aduro Biotech, Inc. (NASDAQ:ADRO) announced its quarterly earnings results on Monday, May, 4th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.05. The biotechnology company had revenue of $13.95 million for the quarter, compared to analyst estimates of $8.81 million. Aduro Biotech had a negative net margin of 230.92% and a negative trailing twelve-month return on equity of 101.73%. What other stocks do shareholders of Aduro Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aduro Biotech investors own include Regulus Therapeutics (RGLS), Exact Sciences (EXAS), Flexion Therapeutics (FLXN), Paratek Pharmaceuticals (PRTK), Nabriva Therapeutics (NBRV), Amarin (AMRN), Anavex Life Sciences (AVXL), Micron Technology (MU), VBI Vaccines (VBIV) and PTC Therapeutics (PTCT). When did Aduro Biotech IPO? Aduro Biotech (ADRO) raised $119 million in an initial public offering on Wednesday, April 15th 2015. The company issued 7,000,000 shares at a price of $17.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers. This page (NASDAQ:ADRO) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aduro Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aduro Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.